Etg Neuroscience Sp. z o.o.

The medical center is at the forefront of research in Parkinson's Disease, focusing on innovative treatments to manage symptoms and improve patient quality of life.

• Suvecaltamide for Residual Tremor
• Minzasolmin for Early-stage Parkinson's
• Tavapadon for Long-term Safety

These studies aim to enhance understanding of Parkinson's Disease pathophysiology and develop therapies that offer better symptom control and disease management.

Our center is dedicated to advancing the treatment of Alzheimer's Disease through cutting-edge research and clinical trials.

• AR1001 for Early Alzheimer's
• RO7269162 for Prodromal Stage

These trials focus on evaluating the efficacy and safety of novel compounds, aiming to slow disease progression and improve cognitive function.

The center is pioneering research in the prevention and treatment of migraine, offering new hope for patients suffering from this debilitating condition.

• Eptinezumab for Chronic Migraine
• MEDI0618 for Episodic Migraine

Our studies are designed to assess the long-term efficacy and safety of these treatments, aiming to reduce the frequency and severity of migraine attacks.

Our institution is committed to improving the management of chronic pain through innovative research and therapeutic approaches.

• VER-01 for Low Back Pain
• Medical Cannabis for Diabetic Neuropathic Pain

These trials focus on understanding the mechanisms of pain and developing effective treatments to enhance patient comfort and quality of life.

The center is exploring new treatments for Perennial Allergic Rhinitis, aiming to alleviate symptoms and improve patient outcomes.

• Lebrikizumab for Nasal Symptoms

Our research seeks to provide effective solutions for managing allergic rhinitis, reducing the impact of symptoms on daily activities.